Related Experiment Video
Updated: Jun 30, 2025
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Stroke Prevention in Blunt Cerebrovascular Injury: Role of Aspirin 81 mg
Sina Asaadi1, Christopher B Khoury1, Julia Han1
1Division of Acute Care Surgery, Department of Surgery, Loma Linda University, Loma Linda, CA.
Insights
Low-dose aspirin (81 mg) effectively prevented strokes in blunt cerebrovascular injury (BCVI) patients. This study suggests aspirin 81 mg is a safe and viable option for BCVI stroke prevention.
Area of Science:
- Trauma surgery
- Vascular surgery
- Neurology
Background:
- Blunt cerebrovascular injury (BCVI) carries a significant stroke risk, ranging from 25% without treatment to under 8% with antithrombotic therapy.
- Optimal BCVI management strategies to prevent stroke remain undefined.
- This study evaluates the efficacy and safety of low-dose aspirin (ASA 81 mg) for BCVI stroke prevention.
Purpose of the Study:
- To assess the effectiveness of aspirin 81 mg in preventing BCVI-related strokes.
- To compare the safety and efficacy of aspirin 81 mg against historical data of aspirin 325 mg and heparin.
- To provide evidence for individualized BCVI management.
Main Methods:
- A single-center retrospective study analyzed 84 adult trauma patients treated with aspirin 81 mg for BCVI between 2013 and 2022.
- Data collected included demographics, injury characteristics, imaging findings, treatment complications, and patient outcomes.
- Medical records were reviewed for detailed analysis.
Main Results:
- Three (3.5%) patients experienced BCVI-related strokes, primarily with higher-grade injuries (Biffl grade II and III).
- No aspirin-related complications were observed in any patient.
- The mean hospital stay was approximately 11 days, with 8 deaths attributed to polytrauma complications.
Conclusions:
- Aspirin 81 mg presents a safe and viable option for preventing BCVI-related strokes, showing comparable or better outcomes than higher-dose aspirin or heparin.
- Individualized, multidisciplinary management is crucial for BCVI patients due to the lack of established guidelines.
- Further prospective research is warranted to confirm the safety and efficacy of aspirin 81 mg in BCVI management.
Background:
The stroke rate in blunt cerebrovascular injury (BCVI) varies from 25% without treatment to less than 8% with antithrombotic therapy. There is no consensus on the optimal management to prevent stroke BCVI. We investigated the efficacy and safety of oral Aspirin (ASA) 81 mg to prevent BCVI-related stroke compared to historically reported stroke rates with ASA 325 mg and heparin.
Methods:
A single-center retrospective study included adult trauma patients who received oral ASA 81 mg for BCVI management between 2013 and 2022. Medical records were reviewed for demographic and injury characteristics, imaging findings, treatment-related complications, and outcomes.
Results:
Eighty-four patients treated with ASA 81 mg for BCVI were identified. The mean age was 41.50 years, and 61.9% were male. The mean Injury Severity Score and Glasgow Coma Scale were 19.82 and 12.12, respectively. A total of 101 vessel injuries were identified, including vertebral artery injuries in 56.4% and carotid artery injuries in 44.6%. Traumatic brain injury was found in 42.9%, and 16.7% of patients had a solid organ injur. Biffl grade I (52.4%) injury was the most common, followed by grade II (37.6%) and grade III (4.9%). ASA 81 mg was started in the first 24 hours in 67.9% of patients, including 20 patients with traumatic brain injury and 8 with solid organ injuries. BCVI-related stroke occurred in 3 (3.5%) patients with Biffl grade II (n = 2) and III (n = 1). ASA-related complications were not identified in any patient. The mean length of stay in the hospital was 10.94 days, and 8 patients died during hospitalization due to complications of polytrauma. Follow-up with computed tomography angiography was performed in 8 (9.5%) patients, which showed improvement in 5 and a stable lesion in 3 at a mean time of 58 days after discharge.
Conclusions:
In the absence of clear guidelines regarding appropriate medication, BCVI management should be individualized case-by-case through a multidisciplinary approach. ASA 81 mg is a viable option for BCVI-related stroke prevention compared to the reported stroke rates (2%-8%) with commonly used antithrombotics like heparin and ASA 325 mg. Future prospective studies are needed to provide insight into the safety and efficacy of the current commonly used agent in managing BCVI.
